Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving granulocyte-macrophage
colony-stimulating factor (GM-CSF) together with rituximab can improve the ability of
rituximab to shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL). The safety of
this combination treatment will also be studied.